Does dapagliflozin maintain consistent efficacy and safety across diuretic subgroups in patients with heart failure and reduced ejection fraction?
Dapagliflozin demonstrates consistent efficacy and safety regardless of baseline diuretic use in patients with HFrEF.
The efficacy and safety of dapagliflozin were consistent across the diuretic subgroups examined in DAPA-HF. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03036124.
Jackson et al. (Thu,) studied this question.